Vertex Pharmaceuticals (Nasdaq: VRTX) announced today a reimbursement agreement with NHS England for eligible sickle cell disease (SCD) patients to access the CRISPR/Cas9 gene-edited therapy, CASGEVY® ...

The FDA has started a priority review of Vertex Pharma and CRISPR Therapeutics’ exagamglogene autotemcel (exa-cel) in sickle cell disease ... foetal haemoglobin (HbF), which can serve as ...

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell ... (HbF) in red blood cells ...

This edit results in the production of high levels of fetal hemoglobin (HbF ... first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of sickle cell disease ...

This edit results in the production of high levels of fetal hemoglobin (HbF; hemoglobin F ... advanced the first-ever CRISPR/Cas9 gene-edited therapy into the clinic to investigate the treatment of ...

Some with severe sickle cell disease in England will now be able to access landmark CRISPR gene editing therapy, according to new health guidelines which were hailed as marking a “significant ...

LONDON — People in England with sickle cell disease will now be able to access the world’s first CRISPR-based medicine under a pricing and reimbursement agreement reached between U.K. health ...

This switches to the adult form once they are born. Crucially foetal haemoglobin is not affected by sickle cell disease, so Crispr acts by dampening down the "switch" that makes the body produce ...

The CRISPR-based gene therapy Casgevy (exagamglogene autotemcel) has been made available to patients with sickle cell disease in England, following positive guidance issued by the National ...

Some with severe sickle cell disease in England will now be able to access landmark CRISPR gene editing therapy, according to new health guidelines which were hailed as marking a “significant shift” ...